ReNeuron Group plc (RNUGF)

USD 0.0

(0.0%)

Market Cap (In USD)

62.89 Thousand

Revenue (In USD)

530 Thousand

Net Income (In USD)

-5.4 Million

Avg. Volume

118.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.0E-4-0.0515
PE
-
EPS
-
Beta Value
0.92
ISIN
GB00BF5G6K95
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
Employee Count
-
Website
https://www.reneuron.com
Ipo Date
2007-04-12
Details
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.